GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » Non Operating Income

Esperion Therapeutics (LTS:0IIM) Non Operating Income : $-45.3 Mil (TTM As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. Esperion Therapeutics's Non Operating Income for the three months ended in Sep. 2024 was $1.6 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-45.3 Mil.

Esperion Therapeutics Non Operating Income Historical Data

The historical data trend for Esperion Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Non Operating Income Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.06 0.52 3.98 2.65 5.29

Esperion Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 1.08 2.78 -50.78 1.58

Esperion Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Esperion Therapeutics Non Operating Income Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Esperion Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » Non Operating Income
Comparable Companies
EBS NIKA SIGA ORGO IRWD AQST AKBA TKNO ELTP BIOA ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB VTRS
Traded in Other Exchanges
ESPR:USA 0ET:Germany 0ET:Germany
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Website
https://www.esperion.com
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines